Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cynvenio Biosystems has entered into a strategic collaboration with the Institute of Regional Health Research for the Region of Southern Denmark at the University of Southern Denmark to conduct a wide array of clinical cancer trials using Cynvenio’s Triple Play LiquidBiopsy platform.
Subscribe to our email newsletter
The Department of Oncology at Vejle Hospital, under the leadership of professor Anders Jakobsen and in corporation with Dr. Torben Frøstrup Hansen, has been identified by the collaborators as a leading center of clinical excellence for the studies.
"One goal of these studies is to better illustrate and define the clinical potential and utility of circulating tumor cell isolation and subsequent multi-omic analysis," said Dr. Jakobsen. "We expect this will help us better understand clinical outcomes and guide decision making for personalized targeted therapy."
In addition to performing enumeration and next-generation DNA sequencing, the researchers will analyze circulating tumor cells for gene expression using Cynvenio’s LiquidBiopsy PD-L1 assay. Patients will also be monitored for real-time treatment response and risk of recurrence following curative surgery.
Cynvenio chief medical officer Paul Song said: "Unlike other existing liquid biopsy technologies, Cynvenio’s Triple Play approach enables the isolation of cell-free DNA, circulating tumor cells, and white blood cells all in one sequencing run. This can then be collectively interrogated to provide clinicians with a better overall understanding of metastatic tumor biology from which more precise therapy can be delivered.
We are excited to partner with this respected scientific team to bring our LiquidBiopsy technology to their clinical research program, which is one of the best in the world."
Cynvenio CEO André de Fusco said: "Since 1942, the Danish government has mandated the collection of all cancer pathology specimens and corresponding clinical records as part of its national cancer registry.
"We are confident our LiquidBiopsy technology will provide a powerful new tool to better analyze the differences between primary tumor, any metastatic deposits, and circulating tumor cells for this program. Ultimately, our collaborators will gain an even deeper understanding of the metastatic tumor microenvironment, which will increase the value of their clinical studies and patient care."